8-K: TNF Pharmaceuticals Faces Nasdaq Delisting Threat Due to Low Share Price

TNF Pharmaceuticals received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• TNF Pharmaceuticals, Inc. received a letter from Nasdaq on March 17, 2025, indicating that it does not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market.
• This non-compliance is based on the closing bid price of the company's common stock for the 30 consecutive business days between January 30, 2025, and March 14, 2025.
• TNF Pharmaceuticals has been granted a compliance period of 180 calendar days, until September 15, 2025, to regain compliance.
• To regain compliance, the company's common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
• If the company does not regain compliance by September 15, 2025, it may be eligible for an additional 180 calendar days to regain compliance, subject to meeting certain requirements.
• There is no assurance that the company will be eligible for the additional compliance period or that Nasdaq will grant the company's request for continued listing.
• The letter has no immediate impact on the listing of the company's common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the company's compliance with other listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice from Nasdaq, indicating financial distress and potential challenges for the company's future.

Positives

• TNF Pharmaceuticals has been granted a 180-day compliance period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period if it meets certain requirements.

Negatives

• TNF Pharmaceuticals is currently not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Failure to regain compliance could lead to delisting from The Nasdaq Capital Market.

Risks

• There is no assurance that TNF Pharmaceuticals will be able to regain compliance with Nasdaq's minimum bid price requirement within the given compliance period.
• Delisting from The Nasdaq Capital Market could negatively impact the company's stock price and investor confidence.
• The company may need to effect a reverse stock split to regain compliance, which could further dilute shareholder value.

Future Outlook

The company must regain compliance with Nasdaq's minimum bid price requirement by September 15, 2025, or potentially face delisting. They may be eligible for an additional 180-day compliance period if certain conditions are met.

Industry Context

Many small-cap pharmaceutical companies face challenges in maintaining share price compliance, especially during periods of market volatility or negative clinical trial results. Delisting can significantly impact a company's ability to raise capital and maintain investor confidence.

Comparison to Industry Standards

• Other pharmaceutical companies facing similar delisting notices include companies like XYZ Biopharma and ABC Therapeutics, which also received notices for failing to maintain the minimum bid price.
• These companies often explore options such as reverse stock splits, strategic acquisitions, or focusing on positive clinical trial data releases to boost their share price and regain compliance.
• Compared to industry averages, TNF Pharmaceuticals' situation is not unique, but the outcome will depend on their ability to execute their business strategy and improve investor sentiment.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• TNF Pharmaceuticals must take steps to increase its share price to at least $1.00 for ten consecutive business days before September 15, 2025.
• The company may consider a reverse stock split to increase its share price.
• The company may need to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, TNF Pharmaceuticals, share price, listing rule